Tradjenta (linagliptin) is generally well tolerated, but it does carry a range of side effects from mild to serious. The most common ones, like nasal congestion and diarrhea, affect a small percentage of users. The rare but serious ones, including pancreatitis and a blistering skin condition, are worth knowing about so you can catch them early.
Common Side Effects
In pooled data from 14 placebo-controlled clinical trials involving over 3,600 patients, only three side effects showed up in at least 2% of Tradjenta users at rates higher than placebo:
- Nasopharyngitis (stuffy nose, sore throat): 7.0% of Tradjenta users vs. 6.1% on placebo
- Diarrhea: 3.3% vs. 3.0% on placebo
- Cough: 2.1% vs. 1.4% on placebo
These numbers tell an important story: the gap between Tradjenta and a sugar pill is slim. Nasopharyngitis, for example, only showed up about 1 percentage point more often with the actual drug. Most people taking Tradjenta won’t notice side effects that feel different from what they’d experience on no medication at all. These common effects typically don’t require stopping the drug and often resolve on their own.
Pancreatitis
Acute pancreatitis is the most talked-about serious risk with Tradjenta and the entire class of drugs it belongs to (DPP-4 inhibitors). During clinical development, a small increased number of pancreatitis cases were detected in linagliptin users compared to placebo. The overall reporting rate for pancreatitis across this drug class falls somewhere between 1 in 1,000 and 1 in 100 patients, though the exact frequency is uncertain because so few cases have occurred in trials.
The hallmark symptom is persistent, severe abdominal pain that sometimes radiates to the back. This isn’t the kind of stomach discomfort you can push through. It’s intense and doesn’t let up. If you develop that kind of pain while taking Tradjenta, it needs immediate medical attention. Pancreatitis can become dangerous quickly if untreated, and the drug should be stopped if pancreatitis is confirmed.
Bullous Pemphigoid
This is one of the more unusual side effects linked to Tradjenta. Bullous pemphigoid is a skin condition that causes large, fluid-filled blisters, often in areas where skin folds or creases, like the upper thighs, armpits, and lower abdomen. It’s rare, but it’s been reported enough in DPP-4 inhibitor users that the FDA added it as a warning.
The condition often starts with intense itching that can persist for weeks or even months before any blisters appear. When blisters do form, they tend to be large and don’t break easily. Their color varies by skin tone: dark pink, brown, or black on darker skin, and yellow, pink, or red on lighter skin. Some people develop sores in the mouth as well. This is not a typical drug rash. If you notice unexplained blistering or prolonged itching that seems to be getting worse, that’s a signal to get evaluated. Stopping the medication typically allows the condition to improve.
Low Blood Sugar Risk
Tradjenta on its own carries a low risk of hypoglycemia (dangerously low blood sugar). The drug works by helping your body release insulin only when blood sugar is elevated, so it rarely pushes levels too far down by itself.
The risk changes significantly when Tradjenta is combined with other diabetes medications, particularly insulin or sulfonylureas. These drugs lower blood sugar through different mechanisms that don’t have the same built-in safety brake. If you’re on one of these combinations, you’re more likely to experience symptoms like shakiness, sweating, confusion, dizziness, or sudden hunger. Your doctor may lower the dose of the other medication to reduce this risk.
Heart Failure
Early concerns about DPP-4 inhibitors and heart failure prompted a large trial called CARMELINA, which specifically tested linagliptin in nearly 7,000 people with type 2 diabetes who were already at high cardiovascular and kidney risk. About 27% of participants had a history of heart failure at the start of the study.
The results were reassuring. Hospitalization for heart failure occurred in 6.0% of linagliptin users compared to 6.5% on placebo, a difference that was not statistically significant. The risk of the combined outcome of cardiovascular death and heart failure hospitalization was also no different between groups. The takeaway from this trial is that Tradjenta does not appear to increase heart failure risk, even in people who already have heart or kidney problems. This sets it apart from at least one other drug in the same class that did show a heart failure signal in trials.
Allergic Reactions
Serious allergic reactions to Tradjenta are rare but have been reported. These can include swelling of the face, lips, tongue, or throat (angioedema), difficulty breathing, and skin reactions like hives or rash. Symptoms can appear at any point during treatment, not just in the first few days. Angioedema in particular can develop suddenly and become a breathing emergency if the swelling affects your airway. Any signs of facial or throat swelling after starting Tradjenta warrant stopping the medication and getting immediate help.
Kidney and Liver Considerations
One practical advantage of Tradjenta over other medications in its class is that it does not require dose adjustments for people with kidney or liver impairment. Most DPP-4 inhibitors are cleared through the kidneys, meaning the dose needs to be reduced as kidney function declines. Tradjenta is primarily eliminated through the gut, so the standard 5 mg dose stays the same regardless of kidney function. This makes it a simpler option for people who have both diabetes and chronic kidney disease, and it means kidney-related side effects from drug accumulation are less of a concern.